Zusammenfassung
Der SCORE wird von der Europäischen Gesellschaft für Kardiologie zur Berechnung des Mortalitätsrisikos über einen Zeitraum von 10 Jahren bei asymptomatischen Erwachsenen empfohlen. Er berücksichtigt die Risikofaktoren Alter, Geschlecht, systolischer Blutdruck, Cholesterin und Rauchen. Das so bestimmte Risiko ist aber nicht immer hinreichend präzise und wird durch die Berücksichtigung renaler Variablen prognostisch erheblich aufgewertet. Im diesem Kontext von besonderer Bedeutung ist sowohl die errechnete glomeruläre Filtrationsrate als auch die Albuminausscheidung im Urin. Für beide Parameter lässt sich eine Steigerung in der Abschätzung des Risikos unabhängig von der eigentlichen SCORE-Klassifizierung belegen. Sie führt oberhalb eines Risikos von 1% zu einer Zuordnung der Patienten zur nächsthöheren Risikostufe im SCORE.
Abstract
The SCORE classification is recommended by the European Society of Cardiology to calculate the mortality risk over a period of 10 years in asymptomatic adults. It takes into account the risk factors of age, gender, systolic blood pressure, cholesterol and smoking, however, the determined risk is not always sufficiently precise and its prognostic performance is improved by considering renal variables. In this context the estimated glomerular filtration rate and urinary albumin excretion are of particular importance. For both parameters an incremental increase in risk regardless of the actual SCORE classification was shown and above a risk of 1% leads to an assignment of the patient to the next level of risk in the SCORE.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Apperloo AJ, De Zeeuw D, De Jong PE (1997) A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51:793–797
Atkins RC, Briganti EM, Lewis JB et al (2005) Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45:281–287
Barnett AH, Bain SC, Bouter P et al (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961
Brugts JJ, Knetsch AM, Mattace-Raso FU et al (2005) Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med 165:2659–2665
Chronic Kidney Disease Prognosis Cosortium; Matsushita K, van der Velde M, Astor BC et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081
De Zeeuw D, Remuzzi G, Parving HH et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921–927
Di Angelantonio E, Danesh J, Eiriksdottir G et al (2007) Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 4:e270
Gaede P, Lund-Andersen H, Parving HH et al (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591
Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426
Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305
Henry RM, Kostense PJ, Bos G et al (2002) Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 62:1402–1407
Hillege HL, Fidler V, Diercks GF et al (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782
Holtkamp FA, De Zeeuw D, Thomas MC et al (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287
Ibsen H, Olsen MH, Wachtell K et al (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198–202
Irie F, Iso H, Sairenchi T et al (2006) The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69:1264–1271
Leoncini G, Ratto E, Viazzi F et al (2008) Global risk stratification in primary hypertension: the role of the kidney. J Hypertens 26:427–432
Mancia G, De Backer G, Dominiczak A et al (2007) 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25:1751–1762
Matsushita K, Selvin E, Bash LD et al (2009) Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 20:2617–2624
Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878
Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 33:1635–1701
Perkovic V, Verdon C, Ninomiya T et al (2008) The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 5:e207
Scheid DC, Mccarthy LH, Lawler FH et al (2001) Screening for microalbuminuria to prevent nephropathy in patients with diabetes: a systematic review of the evidence. J Fam Pract 50:661–668
Schmieder RE, Mann JF, Schumacher H et al (2011) Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22:1353–1364
Schmieder RE, Schrader J, Zidek W et al (2007) Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 96:247–257
Sciarretta S, Valenti V, Tocci G et al (2010) Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy – Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens 28:251–258
Sehestedt T, Jeppesen J, Hansen TW et al (2010) Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 31:883–891
Volpe M, Battistoni A, Tocci G et al (2012) Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens 30:1056–1064
Weiner DE, Tabatabai S, Tighiouart H et al (2006) Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 48:392–401
Yuyun MF, Khaw KT, Luben R et al (2004) Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 33:189–198
Interessenkonflikt
Der korrespondierende Autor weist für sich und seinen Koautoren auf folgende Beziehungen hin: RES und PB haben von verschiedenen Herstellern von RAS-Hemmern Honorare für Vorträge und Beratung sowie Drittmittel für Forschungsprojekte erhalten.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmieder, R., Bramlage, P. Abschätzung des kardiovaskulären Risikos. Nephrologe 8, 128–135 (2013). https://doi.org/10.1007/s11560-012-0688-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-012-0688-x